|
|
|
|
|
Webinar | BRANY
|
Explore ethical and regulatory challenges in neurological gene therapy trials, with expert insights on IRB/IBC collaboration, consent protocols, and oversight for vulnerable populations.
|
|
|
|
|
|
Video | Scout
|
Strong site engagement prevents logistical friction from stalling research. Proactive support and local expertise ensure administrative burdens never stand in the way of clinical progress.
|
|
|
|
|
|
Video | Clinical Leader
|
Donna Rivera of Canal Row Advisors stresses that successful and regulator-trusted AI depends on three fundamentals: high-quality, fit-for-purpose data; transparent and explainable models; and cross-disciplinary collaboration to ensure meaningful clinical impact.
|
|
|
|
|
|
Video | Worldwide Flex
|
The shifting dynamics of clinical research from the current funding dynamic to the increased complexity of drug development, requires a different approach to functional outsourcing to be successful.
|
|
|
|
|
|
Video | Dr. Vince Clinical Research
|
Master the complexities of controlled substance handling, over-encapsulation, and dosing strategies to ensure the data integrity and regulatory compliance of abuse potential assessments.
|
|
|
|
|
|
Video | Revvity Signals Software, Inc.
|
Enable your Data Managers and Medical Monitors to create study-aware custom listings from natural-language requests while maintaining transparency and traceability.
|
|
|
|
|
|
Video | IQVIA Technologies
|
Experience seamless, secure, and flexible eCOA data collection with our application designed for diverse users, compatible with multiple devices, and equipped with offline functionality and robust authentication.
|
|
|
|
|
|
Webinar | CRIO
|
Explore how clinical trial sponsors can benefit from the growing use of electronic source (eSource) technology at research sites.
|
|
|
|
|
|
Video | Clinical Leader
|
In this episode of Trials Without Borders, brought to you by Clinical Leader and FlexPoint Bio, host Elena Sinclair and co-host Ross Jackson go beyond the regulatory landscape to tackle the operational questions that determine whether a UK trial runs on time and on budget.
|
|
|